NFKB1 and COVID-19: Based on the p-value and the number of targets enriched in the pathway and in combination with the literature reports, it was concluded that pathways such as NF-κB, inflammatory bowel disease, (and) RIG-I-like receptor signaling pathway may be potential key pathways for SG in the treatment of COVID-19 (Figure 3B) [29,30,31,32,33].